Deep Dive: Page 10
Industry insights from our journalists
-
Startup biotech Homology Med aims to 'leapfrog' CRISPR competitors
Launched with $44 million in venture funding last month, Homology is developing an alternative, but unproven, approach to gene-editing.
Ned Pagliarulo • June 21, 2016 -
'The sharks are circling:' 5 insights from the Valeant documents
Over 800 pages of internal emails, presentations, and contracts were released by the Senate Special Committee on Aging as part of its ongoing investigation into Valeant's pricing strategies.
Ned Pagliarulo • May 10, 2016 -
Why Inflectra may face greater challenges than Zarxio in winning over US docs
The two drugs are the first biosimilars approved in the U.S., but others look set to join.
Nicole Gray • April 27, 2016 -
Inside the development of Venclexta, AbbVie's new leukemia drug
Venclexta should help bolster AbbVie's oncology portfolio as it works to offset the threat of generic competition to its best-seller Humira.
Ned Pagliarulo • April 22, 2016 -
Biosimilars gain momentum — and pharma leaders are noticing
The FDA has approved two high-profile biosimilars and others await a decision. Respondents to BioPharma Dive’s first State of Drug Development survey picked up on this progress.
Ned Pagliarulo • April 13, 2016 -
Why partnerships are crucial for pushing vaccine R&D forward
As development costs increase, more collaborations between pharma companies, NGOs, and governments will be needed, according to Dr. Jim Tartaglia, global VP of new vaccines projects at Sanofi Pasteur.
Ned Pagliarulo • April 7, 2016 -
After merger with Pfizer implodes, Allergan's acquisition options open up
The Irish drugmaker will get a large influx of cash when its divestment with Teva clears U.S. regulatory authorities.
Ned Pagliarulo • April 6, 2016 -
Patent case in India highlights tensions between public health, protecting innovation
Doctors Without Borders has attempted to block Pfizer's pneumonia vaccine in India, looking to a similar Pfizer patent which the European Patent Office revoked under appeal in 2014.
Ned Pagliarulo • March 24, 2016 -
Citing 'improper conduct,' Valeant attempts to oust former CFO from board
Howard Schiller refused to resign however, and denied wrongdoing related to the company's accounting.
Ned Pagliarulo • March 21, 2016 -
Black box warning order clouds future for Bayer's Essure
The permanent birth control device has had a troubled history, including lawsuits and patient complaints to the FDA.
Nicole Gray • March 9, 2016 -
FDA
Kite, Juno ramping up commercial manufacturing capacity for CAR-T
Both companies expect to generate clinical data on their respective CAR-T therapies sometime in late 2016.
Ned Pagliarulo • March 3, 2016 -
How the opioid crisis convinced these senators to oppose advancing Califf's nomination, in charts
Although the cloture vote to advance Califf's nomination passed overwhelmingly, six senators voted against him—and almost all cited their concerns over the FDA's role in the growing opioid crisis as a reason.
Ned Pagliarulo • Feb. 23, 2016 -
Chasing blockbusters: Does pharma need to change its success strategy?
A new book focusing on the best ways to bring value to healthcare highlights several warning signs that biopharma may want to note as it tries to build winning drugs in a more demanding R&D landscape.
Sy Mukherjee • Feb. 18, 2016 -
One Louisiana doc's made millions blowing the whistle on big pharma. Is that problematic?
Some say the system for rewarding so-called "serial whistleblowers" can create perverse incentives. But watchdog groups like Taxpayers Against Fraud insist the focus should be on the "serial fraudsters" in the industry, and that calling out whistleblowers is missing the forest for the trees.
Sy Mukherjee • Feb. 18, 2016 -
From 'hit' to candidate: Inside Sanofi's massive compound sharing agreement with AZ
In an interview with BioPharma Dive, Sanofi's chief scientific officer also discussed how the company hopes to jumpstart its Zika vaccine development.
Ned Pagliarulo • Feb. 11, 2016 -
Breaking down Super Bowl 50's pharma ads: A bold moment for gut drugs
Two ads that got a lot of attention during the big game last Sunday were AstraZeneca's Movantik commercial for opioid-induced constipation and Valeant's Xifaxan ad for IBS-D. We spoke with Michael Smith, Vice President of the nonprofit patient group G-PACT, about why they were so significant.
Nicole Gray • Feb. 10, 2016 -
BIO CEO 2016: What it will take to achieve Cancer MoonShot 2020
Experts from Bristol-Myers Squibb, Friends of Cancer Research, and others discussed the promise and the perils surrounding the ambitious effort and the development of next-gen cancer meds during a panel at the BIO CEO & Investor Conference in New York.
Nicole Gray • Feb. 10, 2016 -
BIO CEO 2016: Purdue pursues deals, boosting the NIH, Schumer slams Shkreli, & more
Senator Chuck Schumer (D-NY) made a surprise appearance at the event, arguing for greater NIH funding while supporting the industry's role in job creation. And other panels tackled issues ranging from "patent trolls" to declining markets.
Nicole Gray • Feb. 9, 2016 -
Liability: The big biosim legal scuffle the industry should be anticipating
According to attorneys from Goodwin Procter, there's a pretty major consideration in the biosimilar regulatory and legal sphere which has gone under the industry's radar.
Sy Mukherjee • Feb. 4, 2016 -
From blunt force to electrical currents: Cancer treatment in the 21st century
We spoke with Asaf Danziger, CEO of NovoCure, about a new therapy for cancer based on alternating electrical fields.
Nicole Gray • Feb. 3, 2016 -
Damaging House memos reveal calculated drug price increases at Turing, Valeant
Documents reviewed by the House Committee on Oversight and Government Reform reveal Turing and Valeant acquired drugs expressly to increase prices, while designing PR strategies to disguise the impact.
Ned Pagliarulo • Feb. 2, 2016 -
FDA
How the brain disease model of addiction drives innovation in drug development
We spoke with Dr. Tom McLellan, co-founder and board chair of the Treatment Research Institute and a contributor to this week’s issue of NEJM, about whether abuse-deterrent opioids work.
Nicole Gray • Jan. 29, 2016 -
Looking ahead at Lilly's 2016 prospects after a challenging 2015
Lilly's revenues and profits barely grew in 2015 as some of its older drugs faltered. While the company's pipeline took some major hits, renewed investment in oncology and diabetes may spur a better year ahead.
Ned Pagliarulo • Jan. 29, 2016 -
Focus on Brazil: In pursuit of the Zika vaccine
BioPharma Dive spoke with Nuno Antunes, PhD, an analyst at Decision Resources Group, about the potential costs of the Zika pandemic and what Brazil’s regulatory authority and top pharma company are doing to solve the problem.
Nicole Gray • Jan. 27, 2016 -
Sy Mukherjee/BioPharma Dive
Sanofi EVP & former Obama admin official Suresh Kumar on the TPP, drug prices, & Dengue
Kumar's unorthodox path to Sanofi's executive team took him through the world of Indian sports broadcasting and the halls of the White House. We spoke with him during the JPMorgan Healthcare Conference in San Francisco earlier this month about some of the biggest issues that Sanofi, and biopharma at large, faces this year.
Sy Mukherjee • Jan. 26, 2016
Previous
